Advances in the Treatment of Actinic Keratosis: Evidence-Based Approaches for Optimized Outcomes
Monograph
Sponsored by North American Center for Continuing Medical Education, LLC
Faculty
Chair
Darrell S. Rigel, MD
Clinical Professor of Dermatology
New York University
Adjunct Professor of Dermatology
Mount Sinai School of Medicine
New York, New York
Faculty
Brian Berman, MD, PhD
Professor of Dermatology and Internal Medicine
Departments of Dermatology and Cutaneous Surgery
University of Miami Miller School of Medicine
Miami, Florida
Ted Rosen, MD
Professor of Dermatology
Baylor College of Medicine
Houston, Texas
Martin Weinstock, MD, PhD
Professor of Dermatology and Community Health
Brown University
Providence, Rhode Island
Target Audience
This activity is designed for dermatologists and related healthcare professionals who manage patients with actinic keratosis (AK).
Learning Objectives
After completing this activity, participants should be able to:
- Institute effective screening methods to promote early AK diagnosis and minimize progression to squamous cell carcinoma and basal cell carcinoma
- Describe the benefits and limitations of current and emerging AK treatment options, including the impact of mode-of-action on patient outcomes
- Implement evidence-based treatment approaches to optimize AK outcomes
Activity Overview
This accredited monograph is available in PDF format.
To be eligible for documentation of credit, participants must read all monograph content, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.
There is no fee associated with this activity.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this activity.
Release date: December 3, 2009
Expiration date: December 3, 2010
Estimated time to complete: 1 hour
For questions regarding this educational activity, please contact Angela Scarnici at 609-371-1137.
Hardware/Software Requirements
All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
CME Accreditation
North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Independent Clinical Reviewer: David L. Swanson, MD, Department of Dermatology, Mayo Clinic, Scottsdale, Arizona
Planning Committee
The planning committee comprises Brian Berman, MD, PhD, Darrell S. Rigel, MD, Ted Rosen, MD, David L. Swanson, MD, Martin Weinstock, MD, PhD; Mary Johnson, Rich Keenan, Deborah Neveleff, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.
Content editing assistance was provided by medical writer Deborah Neveleff.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Berman: Consultant—Peplin Inc; Scientific advisor—Graceway Pharmaceuticals, LLC, Peplin Inc, Pharmaderm; Speakers bureau—Graceway Pharmaceuticals, LLC, Pharmaderm, sanofi-aventis U.S.
Dr. Rigel: Grant/research support—Bradley Pharmaceuticals Inc, Lumenis Ltd, Neutrogena Corporation; Consultant—Galderma Laboratories, LP, Graceway Pharmaceuticals, LLC, Intendis GmbH, Medicis Pharmaceutical Corporation, Neutrogena Corporation, Peplin Inc; Scientific advisor—Beiersdorf Inc, Graceway Pharmaceuticals, LLC, L’Oreal, Lumenis, Neutrogena Corporation; Speakers bureau—Bradley Pharmaceuticals Inc, Graceway Pharmaceuticals, LLC
Dr. Rosen: Consultant—Graceway Pharmaceuticals, LLC, PharmaDerm; Speakers bureau—Graceway Pharmaceuticals, LLC
Dr. Swanson and Dr. Weinstock have no relevant financial relationships with any commercial interests.
Ms. Johnson, Mr. Keenan, Ms. Neveleff, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty have disclosed the following off-label/unapproved uses of drugs and/or devices will be discussed: the use of sunscreen or retinoids for the prevention of AK; target- and field-directed combination therapy with diclofenac/cryosurgery, 5-fluorouracil/cryosurgery, and imiquimod/cryosurgery; field-directed combination therapy with 5-fluorouracil/imiquimod, 5-fluorouracil/photodynamic therapy, and imiquimod/photodynamic therapy; retinoids for the treatment of AK; imiquimod 2.5% or 3.75%, ingenol mebutate, and betulin for the treatment of AK.
Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors.
NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2009 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Grant Support
Supported by an educational grant from Graceway Pharmaceuticals, LLC
